Harrow Inc (HROW) Stock Price, Quote & News

Company Profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 615 733 4730

Website: www.harrow.com

Address:

1A Burton Hills Boulevard, Suite 200, Nashville, United States

stu4 Jul. 10 at 11:30 AM

$HROW $QURE $REPL $SLS $TWST So F OFF @ezimon …little Chris , can’t take the truth ..move along No, whimps block !!!! Another loser , similar to Matt Kapushit

1 · Reply

stu4 Jul. 10 at 10:31 AM

$HROW $QURE $REPL $SLS $TWST of course when the CEO continues to sell, creates hype of his HD , and never buying shares, one could decide to SHORT !!!

1 · Reply

CFontina Jul. 10 at 2:21 AM

$ETON $HROW It looks like Eton's stock price is going to cross Hrow's again. I remember when Sean had a tiny cock, but now it is looking much bigger than Mark's. Man, was that ever a bad decision for Hrow to dump their position in Eton. Would have been worth a fortune today.

2 · Reply

stu4 Jul. 9 at 11:25 PM

$HROW $QURE $REPL $SLS $TWST another loser that fcuks with dollar stocks…cashless a hole

0 · Reply

Stacks_Edwards Jul. 9 at 7:59 PM

$HROW if we get a 39 I might go all in here.

0 · Reply

MOOSEN Jul. 9 at 6:12 PM

$HROW $QURE $REPL $SLS $TWST THIS DUDE FOR REAL?

2 · Reply

flash9875 Jul. 9 at 6:06 PM

$HROW ok finny…you scalped a little profit…now buy !

0 · Reply

alexpitti Jul. 9 at 5:49 PM

my best short ideas are $HROW $SLS $REPL $TWST and $QURE

5 · Reply

Finnish_boy Jul. 9 at 1:03 PM

$HROW Analysts' estimates 63M-75M.

0 · Reply

Finnish_boy Jul. 9 at 7:35 AM

$HROW Did you guys see this? My best guess is MELT pre-NDA meeting that happens in August. It was in Cantor report. Problem with MELT is that it's only 150M product and Harrow needs partner for other use of cases. Label expansion to eye operations with smaller study is great news though.

1 · Reply

Harrow announces commercial launch of Byooviz in the U.S.

2026-07-01T11:11:21.000Z - 9 days ago

Harrow announces commercial launch of BYOOVIZ in U.S.

Jul 1, 2026, 7:00 AM EDT - 9 days ago

Harrow Announces Commercial Launch of BYOOVIZ® in the United States

Jul 1, 2026, 7:00 AM EDT - 9 days ago

Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow

Jun 10, 2026, 7:00 AM EDT - 4 weeks ago

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

Jun 3, 2026, 9:40 AM EDT - 5 weeks ago

Harrow Transcript: 46th Annual William Blair Growth Stock Conference

Jun 3, 2026, 9:40 AM EDT - 5 weeks ago

Harrow Slides: 46th Annual William Blair Growth Stock Conference

May 27, 2026, 7:00 AM EDT - 6 weeks ago

Harrow to Present at William Blair's 46th Annual Growth Stock Conference

2026-05-15T14:31:15.000Z - 7 weeks ago

Harrow CEO buys $302K, CFO buys $104.7K in common stock

2026-05-14T13:54:22.000Z - 2 months ago